Global Medical Device Podcast powered by Greenlight Guru

Navigating the regulatory landscape for combination products requires understanding how primary modes of action (PMOA) dictate oversight pathways. In this episode, host Etienne Nichols sits down with Jim Fentress, Director of Regulatory Affairs at Galero (a Santa Group company), to unpack the structural differences and hidden pitfalls when medical device and pharmaceutical worlds collide. They discuss how the FDA handles lead agenc...

Many early-stage medical device founders face a major dilemma: how do you prove regulatory maturity to investors and partners before you actually hold a final CE mark or FDA approval? Waiting until the end of a long development cycle creates significant commercial risk. By treating regulatory readiness as a continuous maturity process rather than an all-or-nothing milestone, startups can build trust early and avoid costly late-stag...

In this episode, host Etienne Nichols sits down with Ali Samiian, founder and managing principal of Popular Access Advisors, to demystify the critical and often misunderstood world of MedTech reimbursement. Far too many early-stage medical device companies treat reimbursement as a secondary, post-launch paperwork exercise, only to find that their brilliant, FDA-cleared technology fails because no one has figured out who will pay fo...

Artificial intelligence has officially entered the mainstream cultural zeitgeist, creating a wave of excitement—and a fair share of fatigue—across the medical device industry. In this episode, host Etienne Nichols sits down with Tyler Harmon, biomedical engineer and CEO of Iaso Automated Medical Systems, to cut through the marketing buzzwords. Together, they explore the technical realities behind the technology stack, s...

The medical device industry functions as a highly complex ecosystem where diverse niches—including regulatory affairs, quality assurance, marketing, and reimbursement—must seamlessly interconnect to bring life-saving technologies to life. In this episode, host Etienne Nichols sits down with Sean Smith, a 25-year B2B marketing veteran, journalist, and founder of the weekly LinkedIn newsletter MedTech Leading Voices. Toge...

In this episode, host Etienne Nichols sits down with Michaela Kivett, a seasoned medical device consultant at Greenlight Guru, to break down the complexities of implementing an electronic Quality Management System (eQMS). Drawing from her background in orthopedic implant contract manufacturing and pharmaceutical process engineering, Michaela shares firsthand accounts of the critical inefficiencies that plague traditional paper and ...

The traditional approach to medical device commercialization often treats manufacturing as a distinct, isolated step executed after the design phase is completed. In this episode, Mike Dolphin, CEO of GuideStar Medical Devices, challenges this linear mindset by arguing that manufacturing process development is fundamentally an extension of product development itself. Drawing from his unique background spanning aerospace engineering...

The FDA is actively shaping the regulatory landscape for Artificial Intelligence (AI) and Machine Learning (ML) in real time. As the agency expands its internal expertise through the Digital Health Center of Excellence, FDA reviewers are becoming highly sophisticated. The era of submitting vague algorithm descriptions is over, paving the way for a more level playing field that rewards companies executing documentation correctly.

Nav...

The MedTech industry widely misread the FDA's recent warning letter to Purolea Cosmetics Lab as a direct crackdown on Artificial Intelligence (AI). Host Etienne Nichols challenges this narrative, explaining that viewing the event strictly through an AI lens causes medical device manufacturers to miss the actual compliance lesson. At its core, the Purolea situation is not a story of bad software, but rather a fundamental failure of ...

The medical device industry is undergoing a paradigm shift as Artificial Intelligence (AI) and Machine Learning (ML) transition from novelties into heavily regulated realities. The turning point arrived when the FDA integrated its own internal AI tool, Elsa, into its scientific review and inspection targeting processes. With regulators actively leveraging the technology, MedTech companies can no longer treat AI as a buzzword; it de...

The transition from a cleared medical device to a commercialized product is one of the most perilous phases for a MedTech startup. While founders frequently anticipate the technical and regulatory hurdles of early-stage development, they often underestimate the "commercial valley of death." Success in the modern healthcare economy requires more than a functional prototype and clinical validation; it requires an exact blueprint to n...

In this episode, host Etienne Nichols sits down with industry veteran Mike Drues to explore a critical theme in modern MedTech: the danger of "not knowing what you don't know." The conversation centers on the growing trend of companies making avoidable, "boneheaded" mistakes despite a robust regulatory framework. Mike Drues emphasizes that while technology evolves, the fundamental responsibility for safety and effectiveness remains...

In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with John Schindler, CEO of Liquet Medical, for a "MedTech Founder 101" masterclass. With over 25 years of experience at industry giants like Atrium and Merit Medical, Schindler shares the "painful reality checks" that come when transitioning from the structured umbrella of a large corporation to the high-stakes, resource-dependent world of a start...

In this episode, host Etienne Nichols sits down with Dr. Adam Saltman, Chief Medical Officer at NAMSA, to explore the treacherous "valley of death" that exists between a medical device prototype and the patient. With a unique "triple threat" perspective as a cardiothoracic surgeon, former FDA official, and industry consultant, Dr. Saltman reveals why technical brilliance often fails in the face of commercial reality.

The conversatio...

Sustainability in the medical device industry is far more complex than simple material substitution. It involves a rigorous balancing act between biocompatibility, regulatory requirements, and supply chain logistics. Etienne Nichols sits down with Lucas Pianegonda, founder of Gradical, to explore why the industry is finally moving toward greener solutions and how companies can adapt without sacrificing technical performance.

The con...

In this episode, host Etienne Nichols speaks directly to professionals in industries like automotive, aerospace, and manufacturing who are looking to transition into MedTech. Drawing from his own experience moving from aerospace to medical devices, Etienne demystifies the industry’s high barriers to entry and explains why your existing skills are more valuable than you might think.

The conversation centers on the "three doors"...

In this deep-dive episode, host Etienne Nichols shifts away from the "inspiring" fluff of entrepreneurship to deliver a gritty, practical masterclass for medical device founders. Drawing from his experience judging at MedTech Innovator and speaking with hundreds of founders, Etienne highlights a sobering reality: success in this industry isn't just about having the best technology. It is about getting the right specialized experts ...

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.

The conversat...

In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive prima...